Alkyl or alkoxy substituted S-heterocyclic retinoids
    4.
    发明授权
    Alkyl or alkoxy substituted S-heterocyclic retinoids 失效
    烷基或烷氧基取代的S-杂环类视黄醇

    公开(公告)号:US5391766A

    公开(公告)日:1995-02-21

    申请号:US57949

    申请日:1993-05-05

    摘要: Compounds of the formula ##STR1## in which X is --S--, --SO-- or --SO.sub.2 --; R.sup.1 is C.sub.7-10 -alkyl or C.sub.7-10 -alkoxy; R.sup.2 is a residue of the formula ##STR2## R.sup.3 is carboxy or lower-alkoxycarbonyl; and n is an integer of 1, 2 or 3; and salts of carboxylic acids of formula I can be used for the treatment of autoimmune diseases and diseases having a strong immunological component, such as psoriasis.

    摘要翻译: 其中X是-S-,-SO-或-SO 2 - 的式I的化合物; R1是C7-10-烷基或C7-10-烷氧基; R 2是下式的残基:(a)或(b)R 3是羧基或低级烷氧基羰基; n为1,2或3的整数; 式I的羧酸盐可用于治疗具有强免疫组分的自身免疫性疾病和疾病,例如牛皮癣。

    Stilbene derivatives
    5.
    发明授权
    Stilbene derivatives 失效
    二苯乙烯衍生物

    公开(公告)号:US5250562A

    公开(公告)日:1993-10-05

    申请号:US829666

    申请日:1992-02-03

    摘要: Compounds of the formula ##STR1## wherein R.sup.1 and R.sup.2 each independently are lower-alkyl; or together are alkylene with 3-5 C-atoms in a straight chain; one of the residues R.sup.3 and R.sup.4 is hydrogen and the other is hydrogen or lower-alkyl; R.sup.6 and R.sup.7 are hydrogen or lower-alkyl; R.sup.5 and R.sup.8 are hydrogen, lower-alkyl, lower-alkoxy or halogen; X signifies --O--, --S--, --SO--, --SO.sub.2 -- or --NR.sup.9 ; R.sup.9 is hydrogen, lower-alkyl or acyl; Y is --S(O).sub.m R.sup.10 or --NHet and, where X is --NR.sup.9 --, --S--, --SO-- or --SO.sub.2 --, also --N(R.sup.11).sub.2 or --OR.sup.12 ; R.sup.10 is lower-alkyl; R.sup.11 and R.sup.12 are hydrogen, lower-alkyl or acyl; --NHet is a 5-8 membered, saturated or unsaturated, monocyclic heterocycle attached via a N-atom; n is 2, 3 or 4 and m is 0, 1 or 2, are described. The compounds of formula I are useful as agents for the treatment of disorders such as neoplasms, dermatoses or ageing of the skin.

    摘要翻译: 式Ⅰ的化合物,其中R 1和R 2各自独立地为低级烷基; 或一起是直链中具有3-5个C原子的亚烷基; 残基R3和R4之一是氢,另一个是氢或低级烷基; R6和R7是氢或低级烷基; R5和R8是氢,低级烷基,低级烷氧基或卤素; X表示-O - , - S - , - SO - , - SO 2 - 或-NR 9; R9是氢,低级烷基或酰基; Y是-S(O)m R 10或-NHet,且其中X是-NR 9 - , - S - , - SO-或-SO 2 - ,以及-N(R 11)2或-OR 12; R10为低级烷基; R 11和R 12是氢,低级烷基或酰基; -NHet是通过N-原子连接的5-8元饱和或不饱和的单环杂环; n为2,3或4,m为0,1或2。 式I的化合物可用作治疗诸如赘生物,皮肤病或皮肤老化的病症的药剂。

    Tetrahydronaphthalene and indane derivatives
    7.
    发明授权
    Tetrahydronaphthalene and indane derivatives 失效
    四氢萘和茚满衍生物

    公开(公告)号:US4876349A

    公开(公告)日:1989-10-24

    申请号:US72075

    申请日:1987-07-10

    摘要: The compounds of the formula ##STR1## wherein X and Y are independently --CH.sub.2 -- or >C(CH.sub.3).sub.2 ; Z is --CHR.sup.8 --, >Co, >CR.sup.8 OR.sup.7 , --CHR.sup.8 --CHR.sup.8 --, --CHOR.sup.7 --CH.sub.2 --, --CO--CHOR.sup.7 or --CHOR.sup.7 --CHOR.sup.7 --R.sup.1 is a 5- or 6-membered, monocyclic heterocyclic group which optionally can be C-substituted by halogen, lower-alkyl, lower-alkoxy, acyloxy, nitro, hydroxy, amino, lower-alkylamino or di-lower-alkylamino and/or which can be substituted on a ring --NH-- group by lower-alkyl; R.sup.2 and R.sup.3 are independently hydrogen, lower-alkyl, trifluoromethyl or halogen and one of R.sup.2 and R.sup.3 always is trifluoromethyl or lower-alkyl; R.sup.4 and R.sup.5 are independently hydrogen, alkyl, alkoxy or halogen; R.sup.6 is hydrogen, lower-alkyl or --OR.sup.7 ; R.sup.7 is hydrogen, lower-alkyl or acyl; R.sup.8 is hydrogen or lower-alkyl; and R.sup.7 and R.sup.8 can be the same or different from one another.are useful for the treatment of neoplasms and dermatoses in mammals. The compounds can be manufactured from a corresponding bicyclic component and a heterocyclic component containing the residue R.sup.1 by a Wittig, Horner or Grignard reaction and the optional subsequent transformation of reactive groups.

    摘要翻译: 下式的化合物其中X和Y独立地是-CH 2 - 或> C(CH 3)2; Z是-CHR8-,> Co,> CR8 OR7,-CHR8-CHR8 + 13,-CHOR7-CH2-,-CO-CHOR7或-CHOR7-CHOR7-R1是5-或6-元单环杂环基,其中 任选地可以被卤素,低级烷基,低级烷氧基,酰氧基,硝基,羟基,氨基,低级烷基氨基或二 - 低级 - 烷基氨基和/或可以被低级烷基氨基取代的环-NH-基团上C -烷基; R2和R3独立地是氢,低级烷基,三氟甲基或卤素,R2和R3之一总是三氟甲基或低级烷基; R4和R5独立地是氢,烷基,烷氧基或卤素; R6是氢,低级烷基或-OR7; R7是氢,低级烷基或酰基; R8是氢或低级烷基; 并且R 7和R 8可以相同或不同。 可用于治疗哺乳动物的肿瘤和皮肤病。 化合物可以由对应的双环组分和含有残基R1的杂环组分通过Wittig,Horner或Grignard反应和任选的随后的反应性基团的转化来制备。

    Heterocyclic retinoid compounds
    8.
    发明授权
    Heterocyclic retinoid compounds 失效
    杂环类视黄醇化合物

    公开(公告)号:US07354931B2

    公开(公告)日:2008-04-08

    申请号:US10960372

    申请日:2004-10-07

    IPC分类号: C07D251/02 A61K31/47

    摘要: The current invention provide novel heterocyclic retinoid compounds, methods of treating or preventing chronic obstructive pulmonary disease, cancer and dermatological disorders, pharmaceutical compositions suitable for the treatment or prevention of these disorders and methods for delivering formulations of these retinoids to a mammal having these disorders.

    摘要翻译: 本发明提供了新颖的杂环类视黄醇化合物,治疗或预防慢性阻塞性肺疾病,癌症和皮肤疾病的方法,适于治疗或预防这些病症的药物组合物以及将这些类视色素的制剂输送到具有这些疾病的哺乳动物的方法。

    Treatment of emphysema using RARy selective retinoid agonists
    10.
    发明授权
    Treatment of emphysema using RARy selective retinoid agonists 失效
    使用RARy选择性维甲酸激动剂治疗肺气肿

    公开(公告)号:US06300350B1

    公开(公告)日:2001-10-09

    申请号:US09691967

    申请日:2000-10-18

    IPC分类号: A61K3144

    摘要: This invention provides methods of treating emphysema and other diseases associated with alveolar damage by treatment with an RAR&ggr; selective agonist. In another aspect, this invention provides methods of promoting tropoelastin gene expression and alveolar matrix repair by contacting the pulmonary intestitial fibroblast with an RAR agonist, preferably an RAR&ggr; selective agonist.

    摘要翻译: 本发明提供了通过用RARγ选择性激动剂治疗来治疗与肺泡损伤相关的肺气肿和其它疾病的方法。 另一方面,本发明提供通过使肺内脏成纤维细胞与RAR激动剂,优选RARγ选择性激动剂接触来促进托普拉斯他汀基因表达和肺泡基质修复的方法。